Demir, AtakanMandel, Nil MolinasPaydas, SemraDemir, GokhanEr, OzlemTurhal, Nazim SerdalBavbek, SevilEralp, YesimSaip, Pinar MuallaGuler, Emine NiluferAydiner, AdnanUluc, Basak OyanKilickap, SadettinUskent, NecdetKaradurmus, NuriKaplan, Mehmet AliYanmaz, Mustafa TeomanDemir, HacerAlan, OzkanKorkmaz, TanerOlgun, PolatUysal, Ozlem SonmezAltundag, KadriGunduz, SeydaGunaldi, MeralSari, MuratBeypinar, IsmailBasaran, Gul2023-02-212023-02-212020-01-0110.4274/balkanmedj.galenos.2020.2019.11.143https://hdl.handle.net/11443/2744http://dx.doi.org/10.4274/balkanmedj.galenos.2020.2019.11.143Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2- metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14\%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2- patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.Breast cancerCDK4/6 inhibitorspalbociclibArticleWOS:000518031100008